CD30-expressing
Showing 1 - 25 of >10,000
T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)
Withdrawn
- T Cell Lymphoma
- Brentuximab Vedotin
-
Kansas City, KansasThe University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023
Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)
Not yet recruiting
- Hodgkin Lymphoma
- +2 more
- Chemotherapy
- Cell infusion
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Oct 13, 2023
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)
Recruiting
- Germ Cell Tumor
- Nonseminomatous Germ Cell Tumor
- ATLCAR.CD30 Cells
- +2 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 13, 2022
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)
Recruiting
- Lymphoma
- +7 more
- ATLCAR.CD30 cells
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Houston (autologous CAR.CD30 EBV specific-CTLs)
Active, not recruiting
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- autologous CAR.CD30 EBV specific-CTLs
-
Houston, Texas
- +1 more
Feb 4, 2022
Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)
Terminated
- Hodgkin Lymphoma
- +2 more
- brentuximab vedotin
-
Anaheim, California
- +18 more
Dec 6, 2022
Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)
Recruiting
- Peripheral T Cell Lymphoma
- ATLCAR.CD30 T cells
- +3 more
-
Chapel Hill, North Carolina
- +1 more
Mar 4, 2022
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)
Active, not recruiting
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- CAR.CD30 T cells
-
Chapel Hill, North Carolina
- +2 more
Mar 16, 2022
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 cells)
Active, not recruiting
- Hodgkin Disease
- +8 more
- ATLCAR.CD30 cells
-
Chapel Hill, North Carolina
- +1 more
Mar 2, 2022
Lymphoma, T-Cell, Peripheral Trial in Czechia (Adcetris 50 MG Injection, Endoxan, Doxorubicin)
Not yet recruiting
- Lymphoma, T-Cell, Peripheral
- Adcetris 50 MG Injection
- +4 more
-
Brno, Czechia
- +6 more
Aug 26, 2021
Advanced or Metastatic Solid Tumors Trial in Beijing (CD40 ligand expressing MSLN-CAR T cells, Albumin-bound paclitaxel,
Recruiting
- Advanced or Metastatic Solid Tumors
- CD40 ligand expressing MSLN-CAR T cells
- +2 more
-
Beijing, Beijing, ChinaKaichao Feng
Jan 19, 2023
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)
Not yet recruiting
- Classical Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- GEN3017
- (no location specified)
Aug 25, 2023
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)
Recruiting
- Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
- Classical Hodgkin Lymphoma
- CD30.CAR-EBVST cells
-
Houston, Texas
- +1 more
Jul 20, 2022
Kidney Cancer, Lymphomas, Positron Emission Tomography Trial in Shanghai ([18F]RCCB6 PET Imaging)
Recruiting
- Kidney Cancer
- +2 more
- [18F]RCCB6 PET Imaging
-
Shanghai, ChinaHuashan Hospital
Nov 19, 2023
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)
Not yet recruiting
- NHL, Relapsed, Adult
- +3 more
- KUR-502
- (no location specified)
Aug 2, 2022
Acute Myelogenous Leukemia Trial in Boston (Brentuximab Vedotin, Mitoxantrone, Etoposide)
Completed
- Acute Myelogenous Leukemia
- Brentuximab Vedotin
- +3 more
-
Boston, MassachusettsMassachusetts General Hospital
Apr 12, 2020
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)
Recruiting
- B-cell Lymphoma
- +5 more
- Cyclophosphamide
- +3 more
-
Louisville, KentuckyNorton Cancer Institute
Jan 24, 2023
CNS Lymphoma Trial in Duarte (procedure, biological, drug)
Recruiting
- Central Nervous System Lymphoma
- Aspiration
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Acute Lymphoid Leukemia
- +4 more
- fludarabine
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
CD19 Expressing Malignancies, Hematologic Malignancy Trial in United States (PBCAR19B)
Recruiting
- CD19 Expressing Malignancies
- Hematologic Malignancy
- PBCAR19B
-
Gilbert, Arizona
- +6 more
Nov 8, 2022
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +4 more
-
Duarte, California
- +3 more
Jul 21, 2022
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,
Recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Brentuximab Vedotin
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 4, 2022
Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)
Recruiting
- Lymphoma
- Relapse/Recurrence
- CD30 CAR-T
- Camrelizumab
-
Wuhan, Hubei, China
- +1 more
Apr 8, 2022